These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32866524)

  • 1. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.
    Horska K; Kotolova H; Karpisek M; Babinska Z; Hammer T; Prochazka J; Stark T; Micale V; Ruda-Kucerova J
    Toxicol Appl Pharmacol; 2020 Nov; 406():115214. PubMed ID: 32866524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.
    Kucera J; Horska K; Hruska P; Kuruczova D; Micale V; Ruda-Kucerova J; Bienertova-Vasku J
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jun; 108():110165. PubMed ID: 33152383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model.
    Horska K; Skrede S; Kucera J; Kuzminova G; Suchy P; Micale V; Ruda-Kucerova J
    CNS Neurosci Ther; 2024 Feb; 30(2):e14565. PubMed ID: 38421095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
    Takahashi K; Nakagawasai O; Sakuma W; Nemoto W; Odaira T; Lin JR; Onogi H; Srivastava LK; Tan-No K
    Neuropharmacology; 2019 May; 150():1-14. PubMed ID: 30831160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model.
    Horska K; Kucera J; Drazanova E; Kuzminova G; Amchova P; Hrickova M; Ruda-Kucerova J; Skrede S
    Biomed Pharmacother; 2024 Jul; 176():116763. PubMed ID: 38805968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol.
    Le Pen G; Jay TM; Krebs MO
    J Psychopharmacol; 2011 Jun; 25(6):822-35. PubMed ID: 21088043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
    Gill KM; Cook JM; Poe MM; Grace AA
    Schizophr Bull; 2014 Mar; 40(2):341-50. PubMed ID: 24464874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats.
    Frescura F; Stark T; Tiziani E; Di Martino S; Ruda-Kucerova J; Drago F; Ferraro L; Micale V; Beggiato S
    Pharmacol Rep; 2024 Aug; 76(4):887-894. PubMed ID: 38789891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
    Singh R; Bansal Y; Sodhi RK; Saroj P; Medhi B; Kuhad A
    Toxicol Appl Pharmacol; 2019 Sep; 378():114643. PubMed ID: 31254565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
    Lin EJ; Lee NJ; Slack K; Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I; Herzog H; Sainsbury A
    Neuropharmacology; 2006 Dec; 51(7-8):1129-36. PubMed ID: 16919686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antipsychotics, haloperidol and olanzapine, on the expression of apoptosis-related genes in mouse mHippoE-2 cells and rat hippocampus.
    Osacka J; Kiss A; Bacova Z; Tillinger A
    Endocr Regul; 2023 Jan; 57(1):152-161. PubMed ID: 37561834
    [No Abstract]   [Full Text] [Related]  

  • 13. Aberrant high frequency oscillations recorded in the rat nucleus accumbens in the methylazoxymethanol acetate neurodevelopmental model of schizophrenia.
    Goda SA; Olszewski M; Piasecka J; Rejniak K; Whittington MA; Kasicki S; Hunt MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Aug; 61():44-51. PubMed ID: 25862088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment.
    Stark T; Di Bartolomeo M; Di Marco R; Drazanova E; Platania CBM; Iannotti FA; Ruda-Kucerova J; D'Addario C; Kratka L; Pekarik V; Piscitelli F; Babinska Z; Fedotova J; Giurdanella G; Salomone S; Sulcova A; Bucolo C; Wotjak CT; Starcuk Z; Drago F; Mechoulam R; Di Marzo V; Micale V
    Biochem Pharmacol; 2020 Jul; 177():114004. PubMed ID: 32360362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
    Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
    Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivity to addictive drugs in the methylazoxymethanol (MAM) model of schizophrenia in male and female rats.
    Ruda-Kucerova J; Babinska Z; Amchova P; Stark T; Drago F; Sulcova A; Micale V
    World J Biol Psychiatry; 2017 Mar; 18(2):129-142. PubMed ID: 27223864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole-induced adverse metabolic alterations in polyI:C neurodevelopmental model of schizophrenia in rats.
    Horska K; Ruda-Kucerova J; Drazanova E; Karpisek M; Demlova R; Kasparek T; Kotolova H
    Neuropharmacology; 2017 Sep; 123():148-158. PubMed ID: 28595931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
    Perez-Iglesias R; Crespo-Facorro B; Amado JA; Garcia-Unzueta MT; Ramirez-Bonilla ML; Gonzalez-Blanch C; Martinez-Garcia O; Vazquez-Barquero JL
    J Clin Psychiatry; 2007 Nov; 68(11):1733-40. PubMed ID: 18052567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.
    Ruda-Kucerova J; Babinska Z; Stark T; Micale V
    Neurotox Res; 2017 Jul; 32(1):121-133. PubMed ID: 28421529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.